Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

26 May 2023 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

26 May 2023 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

23 May 2023 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

08 May 2023 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

28 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Presentation of Naxitamab data at AACR

18 Apr 2023 08:00:02 By Nasdaq GlobeNewswire

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

05 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

30 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

21 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

02 Feb 2023 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA

04 Jan 2023 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe

21 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe

16 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Pipeline Update

14 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China

08 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs to Host Annual Research and Development Day in New York

06 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application

01 Dec 2022 16:34:16 By Nasdaq GlobeNewswire

Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

07 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

02 Nov 2022 15:01:00 By Nasdaq GlobeNewswire